Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Ipsen Pharma
Beaufour Ipsen Pharma
MAJ Il y a 4 ans
AN EXPLORATORY, OPEN, TWO-ARM, MATCH-CONTROL, RANDOMISED AND STRATIFIED PILOT PHASE II STUDY ASSESSING THE PREVENTION OF THE ADVERSE EFFECTS OF LONG-TERM HIGH-DOSE GLUCOCORTICOID THERAPY BY GROWTH HORMONE (NutropinAqTM) ADMINISTERED BY SUB-CUTANEOUS ROUTE IN CHILDREN WITH CHRONIC DISEASE
The primary objective of the study is to determine whether the administration of growth hormone will result in the prevention/reduction of adverse effects induced by long-term high-dose glucocorticoid...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ipsen Pharma GmbH
MAJ Il y a 4 ans
Study to investigate the combination of Lanreotide Autogel 120mg and Temozolomid in patients with WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMOURS
The primary study objective is to evaluate the efficacy of Lanreotide Autogel (ATG) 120 mg in combination with Temozolomide in patients with functioning as well as non-functioning, progressive, gastro...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Beaufour Ipsen Pharma S.A.S
MAJ Il y a 4 ans
A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients with upper back myofascial pain syndrome (MPS)
To compare the efficacy of a single application of Dysport (100, 300 or 500 units) injected into 3 to 6 trigger points (TPs) located in the upper back musculature of adults with (MPS) with placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Beaufour Ipsen Pharma
MAJ Il y a 4 ans
EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study
To demonstrate an improvement in skeletal muscle energetics and particularly in mitochondrial oxidative phosphorylation.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Beaufour Ipsen Pharma
MAJ Il y a 4 ans
A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostatin LAR Depot (20 and 30mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated with Carcinoid Syndrome
To evaluate the efficacy of lanreotide Autogel (90 and 120 mg), compared with Sandostatin LAR Depot (20 and 30 mg), in terms of the frequency of target symptom episodes, assessed by the change ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ipsen Pharma
MAJ Il y a 4 ans
A study with tasquinimod, treating patients with hepatocellular, ovarian, renal cell and gastric cancers
To determine the clinical activity of tasquinimod in advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas in patients who progressed after standard therapies Clinical acti...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Ipsen Pharma
MAJ Il y a 4 ans
Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome
Part A The primary study objective is to assess the efficacy of repeated s.c. injections at different doses of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3